- Home
- RPRX vs ROIV Comparison
RPRX vs ROIV Comparison
Compare RPRX & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | ROIV |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5B | 20.7B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RPRX | ROIV |
|---|---|---|
| Price | $49.36 | $27.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $51.40 | $28.94 |
| AVG Volume (30 Days) | 2.5M | ★ 4.5M |
| Earning Date | 05-06-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.78 | N/A |
| Revenue | ★ $2,378,193,000.00 | $29,053,000.00 |
| Revenue This Year | $38.63 | N/A |
| Revenue Next Year | $4.73 | $744.61 |
| P/E Ratio | $27.85 | ★ N/A |
| Revenue Growth | ★ 5.06 | N/A |
| 52 Week Low | $31.97 | $10.58 |
| 52 Week High | $50.08 | $30.33 |
Technical Indicators
Market Signals| Indicator | RPRX | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 60.46 | 43.41 |
| Support Level | $35.34 | $26.94 |
| Resistance Level | N/A | $27.94 |
| Average True Range (ATR) | 0.88 | 0.85 |
| MACD | 0.03 | -0.12 |
| Stochastic Oscillator | 77.82 | 14.42 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.